AKT2 and neoplasm: Individual inhibitors for p110α, p110β, AKT1 or AKT2, or for the p110α/AKT1 combination, slightly decreased tumor growth from days 12–18 of drug treatment in comparison to vehicle controls, however, none of these translated to statistically significant effects at day 35.